NEUROMOD DEVICES NAMES ROSEMARIE TULLY CHIEF OPERATING OFFICER

NEUROMOD DEVICES NAMES ROSEMARIE TULLY CHIEF OPERATING OFFICER

Digital Hub, Rainsford Street, Dublin., April [-], 2020 /PRNewswire/ Neuromod announced today that Rosemarie Tully has been named chief operating officer, effective immediately. Ms. Tully was most recently Chief Business Officer, responsible for business development, corporate and commercial strategy.

In addition to her current responsibilities for corporate development and strategy, Ms. Tully will now assume responsibility for all Neuromod’s operating activities, including manufacturing, supply chain, regulatory, quality and compliance functions. Ms. Tully will continue to report to Dr. Ross O’Neill, chief executive officer of Neuromod.

Ms Tully’s appointment as COO was identified as key to supporting Neuromod’s accelerated growth phase as it transitions from a research and development organisation to large-scale manufacturing and commercialisation of its lead programme, Lenire® for tinnitus. As COO, Ms Tully’s key short-term focus will be on scaling up manufacturing capacity to meet anticipated European demand; and implementing regulatory strategy required to support market entry into the United States.

"I am delighted to announce Rosemarie’s appointment as Chief Operating Officer. Rosemarie’s broad skillset and extensive international experience in senior leadership roles in the Pharma sector have been crucial to the development of Neuromod, since she joined the company in 2018. Rosemarie has also delivered key commercial initiatives like the successful launch of our Lenire® brand in Ireland and Germany. As COO she will continue to support myself and our newly appointed Chief Commercial Officer, Florian Elsäßer as the roll-out of our commercial strategy accelerates in key markets” said Dr Ross O Neill, CEO

Ms. Tully is a registered pharmacist, with more than 20 years of industry experience including senior roles in corporate development and strategy at Sigmoid Pharma (now Sublimity Therapeutics), Elan (now Perrigo), as well as strategy consulting experience at McKinsey & Company. Ms. Tully earned a BSc (Hons) Pharmacy at Trinity College Dublin, Ireland and a master's degree in business administration from INSEAD, France.

About Neuromod Devices Limited
Neuromod, headquartered in the Digital Hub, Dublin, Ireland, is an emerging medical technology company, specialising in the design and development of neuromodulation technologies to address the clinical needs of underserved patient populations who live with chronic and debilitating tinnitus. The company was founded in 2010, by Dr. Ross O’Neill, as a spin-out from Maynooth University. Neuromod has conducted extensive clinical trials to confirm the efficacy of its non-invasive neuromodulation treatment for this extremely common disorder for which no standard of care has yet been established. Tinnitus affects between 10 and 15% of the global population, and the lives of at least 1 in every 100 people worldwide are severely compromised because of the incessant nature of the illusory sound that is often described as a ringing or buzzing in the ears.
www.NeuromodDevices.com.